Company profile
Biohaven Ltd.
NYSE:BHVNBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Opakalim | phase2_3 | — | 9 | active |
| RILUZOLE | phase1 | — | 3 | completed, terminated, withdrawn |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (29)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06874335 | phase1 | recruiting | 2025-03-20 | 2029-03-01 | Biohaven Therapeutics Ltd. | A Phase 1 Study of BHV-1530 in Advanced Solid Tumors |
| NCT06384807 | phase1_2 | recruiting | 2024-04-22 | 2028-02-01 | Biohaven Therapeutics Ltd. | A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors |
| NCT07262268 | phase1 | enrolling_by_invitation | 2026-01-15 | 2026-11-01 | Biohaven Therapeutics Ltd. | A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia |
| NCT07642050 | phase3 | not_yet_recruiting | 2026-06-01 | 2028-09-01 | Biohaven Therapeutics Ltd. | A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy |
| NCT06425159 | phase2_3 | terminated | 2024-06-20 | 2026-03-12 | Biohaven Therapeutics Ltd. | A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures |
FDA applications (0)
No records yet.